Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12744258 | 0.81 | ALDH1A1 (0.50) | ALDH1A1HPGDKDM4EMEN1MAPT | |
| SCHEMBL19009043 | 0.80 | ALDH1A1 (0.44) | ALDH1A1HPGDKDM4EMEN1MAPT | |
| SCHEMBL441605 | 0.78 | CA12 (0.47) | ALDH1A1KDM4EMAPTCASP3MAPK1 | |
| SCHEMBL9485161 | 0.78 | ALDH1A1 (0.40) | ALDH1A1HPGDKDM4EMEN1MAPT | |
| SCHEMBL19009047 | 0.78 | ALDH1A1 (0.43) | ALDH1A1HPGDKDM4EMEN1MAPT | |
| SCHEMBL1500415 | 0.77 | ALDH1A1 (0.55) | ALDH1A1HPGDKDM4EMEN1MAPT | |
| SCHEMBL17303441 | 0.75 | ALDH1A1 (0.38) | ALDH1A1HPGDKDM4EMEN1MAPT | |
| SCHEMBL8730344 | 0.75 | ALDH1A1 (0.38) | ALDH1A1HPGDKDM4EMEN1MAPT | |
| SCHEMBL6318641 | 0.75 | CASP3 (0.52) | ALDH1A1MEN1KMT2ACASP3CES1 | |
| SCHEMBL17193079 | 0.74 | APP (0.48) | ALDH1A1HPGDKDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263540-A1 | SMALL-MOLECULE INHIBITORS OF PROTEIN SYNTHESIS INACTIVATING TOXINS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2011-10-27 | — | — | US | disclosed |
| US-RE41614-E1 | Synthetic analogs of ecteinascidin-743 | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-08-31 | — | — | US | disclosed |
| US-RE41614-E1 | Synthetic analogs of ecteinascidin-743 | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-08-31 | — | — | US | disclosed |
| EP-0314766-B1 | METHOD FOR MAKING THIANTHRENE DIANHYDRIDE AND POLYIMIDES OBTAINED THEREFROM | GEN ELECTRIC (US) | 1993-11-03 | — | — | EP | disclosed |
| US-4864015-A | OXIDATION RESISTANT COMPOSITES | GENERAL ELECTRIC COMPANY (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0314766-A1 | METHOD FOR MAKING THIANTHRENE DIANHYDRIDE AND POLYIMIDES OBTAINED THEREFROM. | GEN ELECTRIC (US) | 1989-05-10 | — | — | EP | disclosed |
| US-4814466-A | FORMING A BISIMIDE FROM AN ALKALI SULFIDE AND AN N-ORGANO-4,5-DIHALOPHTHALIMIDE; HYDROLYSIS AND DEHYDRATION | GENERAL ELECTRIC COMPANY (US) | 1989-03-21 | — | — | US | disclosed |
| WO-1988009353-A1 | METHOD FOR MAKING THIANTHRENE DIANHYDRIDE AND POLYIMIDES OBTAINED THEREFROM | GENERAL ELECTRIC COMPANY (US) | 1988-12-01 | — | — | WO | disclosed |
| US-4681950-A | PHOTOSENSITIZERS | CIBA-GEIGY CORPORATION (US) | 1987-07-21 | — | — | US | disclosed |
| US-4585876-A | PHOTOSENSITIZERS | CIBA-GEIGY CORPORATION (US) | 1986-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263540-A1 | SMALL-MOLECULE INHIBITORS OF PROTEIN SYNTHESIS INACTIVATING TOXINS | MRPS27, MRPS22, MRPS23 | ALDH1A1 4637/4885HPGD 3921/4885KDM4E 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.